Related references
Note: Only part of the references are listed.BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
Shmuel Benenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
Jocelyn Keehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
William Daniel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Licensed Bacille Calmette-Guerin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation
Asimenia Angelidou et al.
VACCINE (2020)
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu et al.
LANCET (2020)
New understanding of the damage of SARS-CoV-2 infection outside the respiratory system
Yuhao Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
Muhammad Adnan Shereen et al.
JOURNAL OF ADVANCED RESEARCH (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Jawad Al-Kassmy et al.
VIRUSES-BASEL (2020)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
Indwiani Astuti et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert A Feldman et al.
VACCINE (2019)
Antibody-mediated protection against MERS-CoV in the murine model
R. R. C. New et al.
VACCINE (2019)
A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
Entao Li et al.
VIRUSES-BASEL (2019)
Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus
Yao Deng et al.
EMERGING MICROBES & INFECTIONS (2018)
Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations
Silvia Sanchez-Ramon et al.
FRONTIERS IN IMMUNOLOGY (2018)
MERS-CoV spike protein: a key target for antivirals
Lanying Du et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Martin Alberer et al.
LANCET (2017)
Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
John J. Suschak et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection
Yufei Wang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)
F. T. Musuamba et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
Anurodh Shankar Agrawal et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine
Jose M. Jimenez-Guardeno et al.
PLOS PATHOGENS (2015)
Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses
Sudhakar Agnihothram et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
Carlos A. DiazGranados et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
Cuiqing Ma et al.
VACCINE (2014)
Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes
Jessica Quintin et al.
CELL HOST & MICROBE (2012)
Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines
Raymond H. See et al.
JOURNAL OF GENERAL VIROLOGY (2008)
Angiotensin-converting enzyme 2 in the brain: properties and future directions
Huijing Xia et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Angiotensin-converting enzyme 2 in lung diseases
Keiji Kuba et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
F Li et al.
SCIENCE (2005)
Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice
ZJ Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus
TW Kim et al.
JOURNAL OF VIROLOGY (2004)
Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine
MS Zhu et al.
IMMUNOLOGY LETTERS (2004)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Share Paper
